-
1
-
-
0347423198
-
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
-
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
-
(2003)
Hypertension
, vol.42
, pp. 1206-1252
-
-
Chobanian, A.V.1
Bakris, G.L.2
Black, H.R.3
Cushman, W.C.4
Green, L.A.5
Izzo Jr., J.L.6
Jones, D.W.7
Materson, B.J.8
Oparil, S.9
Wright Jr., J.T.10
Roccella, E.J.11
-
2
-
-
0037527647
-
2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension
-
2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011-1053.
-
(2003)
J Hypertens
, vol.21
, pp. 1011-1053
-
-
-
3
-
-
0242654867
-
Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively-designed overviews of randomised trials
-
Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527-1535.
-
(2003)
Lancet
, vol.362
, pp. 1527-1535
-
-
Turnbull, F.1
-
4
-
-
0038203004
-
Cardiovascular prevention and blood pressure reduction: A quantitative overview updated until 1 March 2003
-
Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens. 2003;21:1055-1076.
-
(2003)
J Hypertens
, vol.21
, pp. 1055-1076
-
-
Staessen, J.A.1
Wang, J.G.2
Thijs, L.3
-
5
-
-
22144477948
-
Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: Results of prospectively designed overviews of randomized trials
-
Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005;165:1410-1419.
-
(2005)
Arch Intern Med
, vol.165
, pp. 1410-1419
-
-
-
6
-
-
2342652390
-
Adverse prognostic significance of new diabetes in treated hypertensive subjects
-
Verdecchia P, Reboldi G, Angeli F, Borgioni C, Gattobigio R, Filippucci L, Norgiolini S, Bracco C, Porcellati C. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension. 2004;43:963-969.
-
(2004)
Hypertension
, vol.43
, pp. 963-969
-
-
Verdecchia, P.1
Reboldi, G.2
Angeli, F.3
Borgioni, C.4
Gattobigio, R.5
Filippucci, L.6
Norgiolini, S.7
Bracco, C.8
Porcellati, C.9
-
7
-
-
4043124049
-
Cardiovascular therapies and risk for development of diabetes
-
Pepine CJ, Cooper-Dehoff RM. Cardiovascular therapies and risk for development of diabetes. J Am Coll Cardiol. 2004;44:509-512.
-
(2004)
J Am Coll Cardiol
, vol.44
, pp. 509-512
-
-
Pepine, C.J.1
Cooper-Dehoff, R.M.2
-
8
-
-
2942635317
-
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial
-
Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022-2031.
-
(2004)
Lancet
, vol.363
, pp. 2022-2031
-
-
Julius, S.1
Kjeldsen, S.E.2
Weber, M.3
Brunner, H.R.4
Ekman, S.5
Hansson, L.6
Hua, T.7
Laragh, J.8
McInnes, G.T.9
Mitchell, L.10
Plat, F.11
Schork, A.12
Smith, B.13
Zanchetti, A.14
-
9
-
-
0031044480
-
Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis
-
Psaty BM, Smith NL, Siscovick DS, Koepsell TD, Weiss NS, Heckbert SR, Lemaitre RN, Wagner EH, Furberg CD. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA. 1997;277:739-745.
-
(1997)
JAMA
, vol.277
, pp. 739-745
-
-
Psaty, B.M.1
Smith, N.L.2
Siscovick, D.S.3
Koepsell, T.D.4
Weiss, N.S.5
Heckbert, S.R.6
Lemaitre, R.N.7
Wagner, E.H.8
Furberg, C.D.9
-
10
-
-
0029132121
-
Nifedipine. Dose-related increase in mortality in patients with coronary heart disease
-
Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation. 1995;92:1326-1331.
-
(1995)
Circulation
, vol.92
, pp. 1326-1331
-
-
Furberg, C.D.1
Psaty, B.M.2
Meyer, J.V.3
-
11
-
-
0028860846
-
Should calcium antagonists be first line drugs in hypertension?
-
Furberg CD, Psaty BM. Should calcium antagonists be first line drugs in hypertension? Herz. 1995;20:365-369.
-
(1995)
Herz
, vol.20
, pp. 365-369
-
-
Furberg, C.D.1
Psaty, B.M.2
-
12
-
-
0030021828
-
FDA gives calcium channel blockers clean bill of health but warns of short-acting nifedipine hazards
-
Marwick C. FDA gives calcium channel blockers clean bill of health but warns of short-acting nifedipine hazards. JAMA. 1996;275:423-424.
-
(1996)
JAMA
, vol.275
, pp. 423-424
-
-
Marwick, C.1
-
13
-
-
0034627164
-
Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: A meta-analysis of randomised controlled trials
-
Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Cavazzini C, Furberg CD. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet. 2000;356:1949-1954.
-
(2000)
Lancet
, vol.356
, pp. 1949-1954
-
-
Pahor, M.1
Psaty, B.M.2
Alderman, M.H.3
Applegate, W.B.4
Williamson, J.D.5
Cavazzini, C.6
Furberg, C.D.7
-
14
-
-
0035922447
-
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
-
Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
-
(2001)
N Engl J Med
, vol.345
, pp. 851-860
-
-
Lewis, E.J.1
Hunsicker, L.G.2
Clarke, W.R.3
Berl, T.4
Pohl, M.A.5
Lewis, J.B.6
Ritz, E.7
Atkins, R.C.8
Rohde, R.9
Raz, I.10
-
15
-
-
0035922441
-
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
-
Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
-
(2001)
N Engl J Med
, vol.345
, pp. 861-869
-
-
Brenner, B.M.1
Cooper, M.E.2
De Zeeuw, D.3
Keane, W.F.4
Mitch, W.E.5
Parving, H.H.6
Remuzzi, G.7
Snapinn, S.M.8
Zhang, Z.9
Shahinfar, S.10
-
16
-
-
0037145856
-
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial
-
Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288:2421-2431.
-
(2002)
JAMA
, vol.288
, pp. 2421-2431
-
-
Wright Jr., J.T.1
Bakris, G.2
Greene, T.3
Agodoa, L.Y.4
Appel, L.J.5
Charleston, J.6
Cheek, D.7
Douglas-Baltimore, J.G.8
Gassman, J.9
Glassock, R.10
Hebert, L.11
Jamerson, K.12
Lewis, J.13
Phillips, R.A.14
Toto, R.D.15
Middleton, J.P.16
Rostand, S.G.17
-
17
-
-
2642642140
-
Comparative pharmacological properties among calcium channel blockers: T-channel versus L-channel blockade
-
Noll G, Luscher TF. Comparative pharmacological properties among calcium channel blockers: T-channel versus L-channel blockade. Cardiology. 1998;(89 Suppl 1):10-15.
-
(1998)
Cardiology
, Issue.89 SUPPL. 1
, pp. 10-15
-
-
Noll, G.1
Luscher, T.F.2
-
19
-
-
0027089915
-
Selectivity scale of calcium antagonists in the human cardiovascular system based on in vitro studies
-
Godfraind T, Salomone S, Dessy C, Verhelst B, Dion R, Schoevaerts JC. Selectivity scale of calcium antagonists in the human cardiovascular system based on in vitro studies. J Cardiovasc Pharmacol. 1992;20(Suppl 5):S34-S41.
-
(1992)
J Cardiovasc Pharmacol
, vol.20
, Issue.5 SUPPL.
-
-
Godfraind, T.1
Salomone, S.2
Dessy, C.3
Verhelst, B.4
Dion, R.5
Schoevaerts, J.C.6
-
20
-
-
0030049628
-
Opie ••. luteinizing hormone (LH). Calcium channel antagonists in the treatment of coronary artery disease: Fundamental pharmacological properties relevant to clinical use
-
Opie ••. luteinizing hormone (LH). Calcium channel antagonists in the treatment of coronary artery disease: fundamental pharmacological properties relevant to clinical use. Prog Cardiovasc Dis. 1996;38:273-290.
-
(1996)
Prog Cardiovasc Dis
, vol.38
, pp. 273-290
-
-
-
22
-
-
0034106766
-
Felodipine improves left ventricular emptying in patients with chronic heart failure: V-HeFT III echocardiographic substudy of multicenter reproducibility and detecting functional change
-
Wong M, Germanson T, Taylor WR, Cohen IS, Perry G, Baruch L, Deedwania P, Lopez B, Cohn JN. Felodipine improves left ventricular emptying in patients with chronic heart failure: V-HeFT III echocardiographic substudy of multicenter reproducibility and detecting functional change. J Card Fail. 2000;6:19-28.
-
(2000)
J Card Fail
, vol.6
, pp. 19-28
-
-
Wong, M.1
Germanson, T.2
Taylor, W.R.3
Cohen, I.S.4
Perry, G.5
Baruch, L.6
Deedwania, P.7
Lopez, B.8
Cohn, J.N.9
-
23
-
-
0033973435
-
Efficacy and safety of calcium channel blockers in heart failure: Focus on recent trials with second-generation dihydropyridines
-
de Vries RJ, van Veldhuisen DJ, Dunselman PH. Efficacy and safety of calcium channel blockers in heart failure: focus on recent trials with second-generation dihydropyridines. Am Heart J. 2000;139(2 Pt 1):185-194.
-
(2000)
Am Heart J
, vol.139
, Issue.2 PART 1
, pp. 185-194
-
-
De Vries, R.J.1
Van Veldhuisen, D.J.2
Dunselman, P.H.3
-
24
-
-
0007410805
-
Effect of amlodipine on morbidity and mortality in severe chronic heart failure
-
Prospective Randomized Amlodipine Survival Evaluation Study Group
-
Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, Miller AB, Neuberg GW, Frid D, Wertheimer JH, Cropp AB, DeMets DL. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med. 1996;335:1107-1114.
-
(1996)
N Engl J Med
, vol.335
, pp. 1107-1114
-
-
Packer, M.1
O'Connor, C.M.2
Ghali, J.K.3
Pressler, M.L.4
Carson, P.E.5
Belkin, R.N.6
Miller, A.B.7
Neuberg, G.W.8
Frid, D.9
Wertheimer, J.H.10
Cropp, A.B.11
DeMets, D.L.12
-
25
-
-
0035818884
-
A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure
-
Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-1675.
-
(2001)
N Engl J Med
, vol.345
, pp. 1667-1675
-
-
Cohn, J.N.1
Tognoni, G.2
-
26
-
-
0344373794
-
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
-
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
-
(2002)
JAMA
, vol.288
, pp. 2981-2997
-
-
-
27
-
-
2942695964
-
Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial
-
Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L, Hua T, Laragh JH, McInnes GT, Mitchell L, Plat F, Schork MA, Smith B, Zanchetti A. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet. 2004;363:2049-2051.
-
(2004)
Lancet
, vol.363
, pp. 2049-2051
-
-
Weber, M.A.1
Julius, S.2
Kjeldsen, S.E.3
Brunner, H.R.4
Ekman, S.5
Hansson, L.6
Hua, T.7
Laragh, J.H.8
McInnes, G.T.9
Mitchell, L.10
Plat, F.11
Schork, M.A.12
Smith, B.13
Zanchetti, A.14
-
28
-
-
0345492460
-
A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): A randomized controlled trial
-
Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M, Erdine S, Bristol HA, Kolb HR, Bakris GL, Cohen JD, Parmley WW. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290:2805-2816.
-
(2003)
JAMA
, vol.290
, pp. 2805-2816
-
-
Pepine, C.J.1
Handberg, E.M.2
Cooper-DeHoff, R.M.3
Marks, R.G.4
Kowey, P.5
Messerli, F.H.6
Mancia, G.7
Cangiano, J.L.8
Garcia-Barreto, D.9
Keltai, M.10
Erdine, S.11
Bristol, H.A.12
Kolb, H.R.13
Bakris, G.L.14
Cohen, J.D.15
Parmley, W.W.16
-
29
-
-
0037851836
-
Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial
-
Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, Neaton JD, Grimm RH, Jr., Hansson L, Lacourciere Y, Muller J, Sleight P, Weber MA, Williams G, Wittes J, Zanchetti A, Anders RJ. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA. 2003;289:2073-2082.
-
(2003)
JAMA
, vol.289
, pp. 2073-2082
-
-
Black, H.R.1
Elliott, W.J.2
Grandits, G.3
Grambsch, P.4
Lucente, T.5
White, W.B.6
Neaton, J.D.7
Grimm Jr., R.H.8
Hansson, L.9
Lacourciere, Y.10
Muller, J.11
Sleight, P.12
Weber, M.A.13
Williams, G.14
Wittes, J.15
Zanchetti, A.16
Anders, R.J.17
-
30
-
-
0034997768
-
Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial
-
ASCOT investigators
-
Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators. J Hypertens. 2001;19:1139-1147.
-
(2001)
J Hypertens
, vol.19
, pp. 1139-1147
-
-
Sever, P.S.1
Dahlof, B.2
Poulter, N.R.3
Wedel, H.4
Beevers, G.5
Caulfield, M.6
Collins, R.7
Kjeldsen, S.E.8
McInnes, G.T.9
Mehlsen, J.10
Nieminen, M.11
O'Brien, E.12
Ostergren, J.13
-
31
-
-
23744493793
-
Clinical trials update from the European Society of Cardiology Heart Failure meeting and the American College of Cardiology: Darbepoetin alfa study, ECHOS, and ASCOT-BPLA
-
Cleland JG, Coletta AP, Clark AL, Velavan P, Ingle L. Clinical trials update from the European Society of Cardiology Heart Failure meeting and the American College of Cardiology: Darbepoetin alfa study, ECHOS, and ASCOT-BPLA. Eur J Heart Fail. 2005;7:937-939.
-
(2005)
Eur J Heart Fail
, vol.7
, pp. 937-939
-
-
Cleland, J.G.1
Coletta, A.P.2
Clark, A.L.3
Velavan, P.4
Ingle, L.5
-
32
-
-
0034730027
-
Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) study
-
Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, Lanke J, de Faire U, Dahlof B, Karlberg BE. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet. 2000;356:359-365.
-
(2000)
Lancet
, vol.356
, pp. 359-365
-
-
Hansson, L.1
Hedner, T.2
Lund-Johansen, P.3
Kjeldsen, S.E.4
Lindholm, L.H.5
Syvertsen, J.O.6
Lanke, J.7
De Faire, U.8
Dahlof, B.9
Karlberg, B.E.10
-
33
-
-
0029845252
-
Newer approaches to antihypertensive therapy. Use of fixed-dose combination therapy
-
Epstein M, Bakris G. Newer approaches to antihypertensive therapy. Use of fixed-dose combination therapy. Arch Intern Med. 1996;156:1969-1978.
-
(1996)
Arch Intern Med
, vol.156
, pp. 1969-1978
-
-
Epstein, M.1
Bakris, G.2
-
34
-
-
0034074955
-
Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes
-
Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care. 2000;23(Suppl 2):B54-B64.
-
(2000)
Diabetes Care
, vol.23
, Issue.2 SUPPL.
-
-
Estacio, R.O.1
Jeffers, B.W.2
Gifford, N.3
Schrier, R.W.4
-
35
-
-
0032513878
-
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
-
HOT Study Group
-
Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755-1762.
-
(1998)
Lancet
, vol.351
, pp. 1755-1762
-
-
Hansson, L.1
Zanchetti, A.2
Carruthers, S.G.3
Dahlof, B.4
Elmfeldt, D.5
Julius, S.6
Menard, J.7
Rahn, K.H.8
Wedel, H.9
Westerling, S.10
-
36
-
-
0029161079
-
The risk of myocardial infarction associated with antihypertensive drug therapies
-
Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weiss NS, Rosendaal FR, Lemaitre RN, Smith NL, Wahl PW. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 1995;274:620-625.
-
(1995)
JAMA
, vol.274
, pp. 620-625
-
-
Psaty, B.M.1
Heckbert, S.R.2
Koepsell, T.D.3
Siscovick, D.S.4
Raghunathan, T.E.5
Weiss, N.S.6
Rosendaal, F.R.7
Lemaitre, R.N.8
Smith, N.L.9
Wahl, P.W.10
-
37
-
-
0034627183
-
Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials
-
Blood Pressure Lowering Treatment Trialists' Collaboration
-
Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet. 2000;356:1955-1964.
-
(2000)
Lancet
, vol.356
, pp. 1955-1964
-
-
Neal, B.1
MacMahon, S.2
Chapman, N.3
-
38
-
-
0037341815
-
Outcomes with nifedipine GITS or co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT)
-
Mancia G, Brown M, Castaigne A, De LP, Palmer CR, Rosenthal T, Wagener G, Ruilope LM. Outcomes with nifedipine GITS or co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension. 2003;41:431-436.
-
(2003)
Hypertension
, vol.41
, pp. 431-436
-
-
Mancia, G.1
Brown, M.2
Castaigne, A.3
De, L.P.4
Palmer, C.R.5
Rosenthal, T.6
Wagener, G.7
Ruilope, L.M.8
-
39
-
-
0034729993
-
Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)
-
Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000;356:366-372.
-
(2000)
Lancet
, vol.356
, pp. 366-372
-
-
Brown, M.J.1
Palmer, C.R.2
Castaigne, A.3
De Leeuw, P.W.4
Mancia, G.5
Rosenthal, T.6
Ruilope, L.M.7
-
40
-
-
11144356621
-
Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial
-
Staessen JA, Thijisq L, Fagard R, Celis H, Birkenhager WH, Bulpitt CJ, de Leeuw PW, Fletcher AE, Forette F, Leonetti G, McCormack P, Nachev C, O'Brien E, Rodicio JL, Rosenfeld J, Sarti C, Tuomilehto J, Webster J, Yodfat Y, Zanchetti A. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J Hypertens. 2004;22:847-857.
-
(2004)
J Hypertens
, vol.22
, pp. 847-857
-
-
Staessen, J.A.1
Thijisq, L.2
Fagard, R.3
Celis, H.4
Birkenhager, W.H.5
Bulpitt, C.J.6
De Leeuw, P.W.7
Fletcher, A.E.8
Forette, F.9
Leonetti, G.10
McCormack, P.11
Nachev, C.12
O'Brien, E.13
Rodicio, J.L.14
Rosenfeld, J.15
Sarti, C.16
Tuomilehto, J.17
Webster, J.18
Yodfat, Y.19
Zanchetti, A.20
more..
-
41
-
-
20444427156
-
Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: Principal results of a prospective randomized controlled study (MOSES)
-
Schrader J, Luders S, Kulschewski A, Hammersen F, Plate K, Berger J, Zidek W, Dominiak P, Diener HC. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke. 2005;36:1218-1226.
-
(2005)
Stroke
, vol.36
, pp. 1218-1226
-
-
Schrader, J.1
Luders, S.2
Kulschewski, A.3
Hammersen, F.4
Plate, K.5
Berger, J.6
Zidek, W.7
Dominiak, P.8
Diener, H.C.9
-
42
-
-
1642456664
-
Beta- and alpha-adrenergic cross-signaling for L-type Ca current is impaired in transgenic mice with constitutive activation of epsilonPKC
-
Yue Y, Qu Y, Boutjdir M. Beta- and alpha-adrenergic cross-signaling for L-type Ca current is impaired in transgenic mice with constitutive activation of epsilonPKC. Biochem Biophys Res Commun. 2004;314:749-754.
-
(2004)
Biochem Biophys Res Commun
, vol.314
, pp. 749-754
-
-
Yue, Y.1
Qu, Y.2
Boutjdir, M.3
-
43
-
-
0343674495
-
Changes in Ca(2+) cycling proteins underlie cardiac action potential prolongation in a pressure-overloaded guinea pig model with cardiac hypertrophy and failure
-
Ahmmed GU, Dong PH, Song G, Ball NA, Xu Y, Walsh RA, Chiamvimonvat N. Changes in Ca(2+) cycling proteins underlie cardiac action potential prolongation in a pressure-overloaded guinea pig model with cardiac hypertrophy and failure. Circ Res. 2000;86:558-570.
-
(2000)
Circ Res
, vol.86
, pp. 558-570
-
-
Ahmmed, G.U.1
Dong, P.H.2
Song, G.3
Ball, N.A.4
Xu, Y.5
Walsh, R.A.6
Chiamvimonvat, N.7
-
44
-
-
0036190137
-
Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes
-
Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 2002;61:1086-1097.
-
(2002)
Kidney Int
, vol.61
, pp. 1086-1097
-
-
Schrier, R.W.1
Estacio, R.O.2
Esler, A.3
Mehler, P.4
-
45
-
-
20244371503
-
Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
-
Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT Jr, Whelton PK, Barzilay J, Batuman V, Eckfeldt JH, Farber M, Henriquez M, Kopyt N, Louis GT, Saklayen M, Stanford C, Walworth C, Ward H, Wiegmann T. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2005;165:936-946.
-
(2005)
Arch Intern Med
, vol.165
, pp. 936-946
-
-
Rahman, M.1
Pressel, S.2
Davis, B.R.3
Nwachuku, C.4
Wright Jr., J.T.5
Whelton, P.K.6
Barzilay, J.7
Batuman, V.8
Eckfeldt, J.H.9
Farber, M.10
Henriquez, M.11
Kopyt, N.12
Louis, G.T.13
Saklayen, M.14
Stanford, C.15
Walworth, C.16
Ward, H.17
Wiegmann, T.18
-
46
-
-
4644221457
-
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
-
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296-1305.
-
(2004)
N Engl J Med
, vol.351
, pp. 1296-1305
-
-
Go, A.S.1
Chertow, G.M.2
Fan, D.3
McCulloch, C.E.4
Hsu, C.Y.5
-
47
-
-
0037222964
-
Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community
-
Manjunath G, Tighiouart H, Ibrahim H, Macleod B, Salem DN, Griffith JL, Coresh J, Levey AS, Sarnak MJ. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol. 2003;41:47-55.
-
(2003)
J Am Coll Cardiol
, vol.41
, pp. 47-55
-
-
Manjunath, G.1
Tighiouart, H.2
Ibrahim, H.3
Macleod, B.4
Salem, D.N.5
Griffith, J.L.6
Coresh, J.7
Levey, A.S.8
Sarnak, M.J.9
-
48
-
-
84858539317
-
-
www.USRDS.org. Accessed June, 20 2005.
-
-
-
-
49
-
-
0035989568
-
Microalbuminuria: Marker of vascular dysfunction, risk factor for cardiovascular disease
-
Garg JP, Bakris GL. Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med. 2002;7:35-43.
-
(2002)
Vasc Med
, vol.7
, pp. 35-43
-
-
Garg, J.P.1
Bakris, G.L.2
-
50
-
-
19944432108
-
Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: Losartan intervention for endpoint reduction in hypertension study
-
Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlof B, Devereux RB, de FU, Fyhrquist F, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wan Y. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension. 2005;45:198-202.
-
(2005)
Hypertension
, vol.45
, pp. 198-202
-
-
Ibsen, H.1
Olsen, M.H.2
Wachtell, K.3
Borch-Johnsen, K.4
Lindholm, L.H.5
Mogensen, C.E.6
Dahlof, B.7
Devereux, R.B.8
De, F.U.9
Fyhrquist, F.10
Julius, S.11
Kjeldsen, S.E.12
Lederballe-Pedersen, O.13
Nieminen, M.S.14
Omvik, P.15
Oparil, S.16
Wan, Y.17
-
51
-
-
20244382844
-
The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: Results of the African American Study of Kidney Disease and Hypertension
-
Lea J, Greene T, Hebert L, Lipkowitz M, Massry S, Middleton J, Rostand SG, Miller E, Smith W, Bakris GL. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American Study of Kidney Disease and Hypertension. Arch Intern Med. 2005;165:947-953.
-
(2005)
Arch Intern Med
, vol.165
, pp. 947-953
-
-
Lea, J.1
Greene, T.2
Hebert, L.3
Lipkowitz, M.4
Massry, S.5
Middleton, J.6
Rostand, S.G.7
Miller, E.8
Smith, W.9
Bakris, G.L.10
-
52
-
-
2442680120
-
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL
-
De Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 2004;65:2309-2320.
-
(2004)
Kidney Int
, vol.65
, pp. 2309-2320
-
-
De Zeeuw, D.1
Remuzzi, G.2
Parving, H.H.3
Keane, W.F.4
Zhang, Z.5
Shahinfar, S.6
Snapinn, S.7
Cooper, M.E.8
Mitch, W.E.9
Brenner, B.M.10
-
53
-
-
0035723259
-
Proteinuria as a modifiable risk factor for the progression of non- diabetic renal disease
-
Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, Marcantoni C, de Jong PE, de Zeeuw D, Shahinfar S, Ruggenenti P, Remuzzi G, Levey AS. Proteinuria as a modifiable risk factor for the progression of non- diabetic renal disease. Kidney Int. 2001;60:1131-1140.
-
(2001)
Kidney Int
, vol.60
, pp. 1131-1140
-
-
Jafar, T.H.1
Stark, P.C.2
Schmid, C.H.3
Landa, M.4
Maschio, G.5
Marcantoni, C.6
De Jong, P.E.7
De Zeeuw, D.8
Shahinfar, S.9
Ruggenenti, P.10
Remuzzi, G.11
Levey, A.S.12
-
54
-
-
3242668147
-
Clinical implications of blockade of the renin-angiotensin system in management of hypertension
-
Chua DY, Bakris GL. Clinical implications of blockade of the renin-angiotensin system in management of hypertension. Contrib Nephrol. 2004;143:105-116.
-
(2004)
Contrib Nephrol
, vol.143
, pp. 105-116
-
-
Chua, D.Y.1
Bakris, G.L.2
-
55
-
-
0031802190
-
Antihypertensive treatment of patients with proteinuric renal diseases: Risks or benefits of calcium channel blockers?
-
Kloke HJ, Branten AJ, Huysmans FT, Wetzels JF. Antihypertensive treatment of patients with proteinuric renal diseases: risks or benefits of calcium channel blockers? Kidney Int. 1998;53:1559-1573.
-
(1998)
Kidney Int
, vol.53
, pp. 1559-1573
-
-
Kloke, H.J.1
Branten, A.J.2
Huysmans, F.T.3
Wetzels, J.F.4
-
56
-
-
0029961207
-
Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy
-
Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int. 1996;50:1641-1650.
-
(1996)
Kidney Int
, vol.50
, pp. 1641-1650
-
-
Bakris, G.L.1
Copley, J.B.2
Vicknair, N.3
Sadler, R.4
Leurgans, S.5
-
57
-
-
0031657169
-
Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy
-
Bakris GL, Weir MR, DeQuattro V, McMahon FG. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int. 1998;54:1283-1289.
-
(1998)
Kidney Int
, vol.54
, pp. 1283-1289
-
-
Bakris, G.L.1
Weir, M.R.2
DeQuattro, V.3
McMahon, F.G.4
-
58
-
-
2442703942
-
Differential effects of calcium antagonist subclasses on markers of nephropathy progression
-
Bakris GL, Weir MR, Secic M, Campbell B, Weis-McNulty A. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int. 2004;65:1991-2002.
-
(2004)
Kidney Int
, vol.65
, pp. 1991-2002
-
-
Bakris, G.L.1
Weir, M.R.2
Secic, M.3
Campbell, B.4
Weis-McNulty, A.5
-
59
-
-
0031657216
-
Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy
-
Smith AC, Toto R, Bakris GL. Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney Int. 1998;54:889-896.
-
(1998)
Kidney Int
, vol.54
, pp. 889-896
-
-
Smith, A.C.1
Toto, R.2
Bakris, G.L.3
-
60
-
-
0032946830
-
Class differences in the effects of calcium channel blockers in the rat remnant kidney model
-
Griffin KA, Picken MM, Bakris GL, Bidani AK. Class differences in the effects of calcium channel blockers in the rat remnant kidney model. Kidney Int. 1999;55:1849-1860.
-
(1999)
Kidney Int
, vol.55
, pp. 1849-1860
-
-
Griffin, K.A.1
Picken, M.M.2
Bakris, G.L.3
Bidani, A.K.4
-
61
-
-
2442657836
-
Effects of calcium channel blockers on "dynamic" and "steady-state step" renal autoregulation
-
Griffin KA, Hacioglu R, bu-Amarah I, Loutzenhiser R, Williamson GA, Bidani AK. Effects of calcium channel blockers on "dynamic" and "steady-state step" renal autoregulation. Am J Physiol Renal Physiol. 2004;286:F1136-F1143.
-
(2004)
Am J Physiol Renal Physiol
, vol.286
-
-
Griffin, K.A.1
Hacioglu, R.2
Bu-Amarah, I.3
Loutzenhiser, R.4
Williamson, G.A.5
Bidani, A.K.6
-
62
-
-
0035715175
-
Comparative effects of selective T- and L-type calcium channel blockers in the remnant kidney model
-
Griffin KA, Picken M, Bakris GL, Bidani AK. Comparative effects of selective T- and L-type calcium channel blockers in the remnant kidney model. Hypertension. 2001;37:1268-1272.
-
(2001)
Hypertension
, vol.37
, pp. 1268-1272
-
-
Griffin, K.A.1
Picken, M.2
Bakris, G.L.3
Bidani, A.K.4
-
63
-
-
0038724678
-
The verapamil versus amlodipine in nondiabetic nephropathies treated with trandolapril (VVANNTT) study
-
Boero R, Rollino C, Massara C, Berto IM, Perosa P, Vagelli G, Lanfranco G, Quarello F. The verapamil versus amlodipine in nondiabetic nephropathies treated with trandolapril (VVANNTT) study. Am J Kidney Dis. 2003;42:67-75.
-
(2003)
Am J Kidney Dis
, vol.42
, pp. 67-75
-
-
Boero, R.1
Rollino, C.2
Massara, C.3
Berto, I.M.4
Perosa, P.5
Vagelli, G.6
Lanfranco, G.7
Quarello, F.8
-
64
-
-
0038155497
-
Effects of blood pressure level on progression of diabetic nephropathy: Results from the RENAAL study
-
Bakris GL, Weir MR, Shanifar S, Zhang Z, Douglas J, van Dijk DJ, Brenner BM. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med. 2003;163:1555-1565.
-
(2003)
Arch Intern Med
, vol.163
, pp. 1555-1565
-
-
Bakris, G.L.1
Weir, M.R.2
Shanifar, S.3
Zhang, Z.4
Douglas, J.5
Van Dijk, D.J.6
Brenner, B.M.7
-
65
-
-
0035846616
-
ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary a Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure)
-
developed in collaboration with the International Society for Heart and Lung Transplantation; endorsed by the Heart Failure Society of America
-
Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, Ganiats TG, Goldstein S, Gregoratos G, Jessup ML, Noble RJ, Packer M, Silver MA, Stevenson LW, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Jacobs AK, Hiratzka LF, Russell RO, Smith SC Jr. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary a. report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the International Society for Heart and Lung Transplantation; endorsed by the Heart Failure Society of America. Circulation. 2001;104:2996-3007.
-
(2001)
Circulation
, vol.104
, pp. 2996-3007
-
-
Hunt, S.A.1
Baker, D.W.2
Chin, M.H.3
Cinquegrani, M.P.4
Feldman, A.M.5
Francis, G.S.6
Ganiats, T.G.7
Goldstein, S.8
Gregoratos, G.9
Jessup, M.L.10
Noble, R.J.11
Packer, M.12
Silver, M.A.13
Stevenson, L.W.14
Gibbons, R.J.15
Antman, E.M.16
Alpert, J.S.17
Faxon, D.P.18
Fuster, V.19
Gregoratos, G.20
Jacobs, A.K.21
Hiratzka, L.F.22
Russell, R.O.23
Smith Jr., S.C.24
more..
-
66
-
-
3042819708
-
K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease
-
K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43(5 Suppl 2):1-290.
-
(2004)
Am J Kidney Dis
, vol.43
, Issue.5 SUPPL. 2
, pp. 1-290
-
-
|